Chiasma (NASDAQ:CHMA) is scheduled to be releasing its earnings data after the market closes on Wednesday, March 14th. Analysts expect Chiasma to post earnings of ($0.23) per share for the quarter.
Chiasma (CHMA) opened at $1.58 on Tuesday. The stock has a market cap of $38.40 and a PE ratio of -1.35. Chiasma has a twelve month low of $1.25 and a twelve month high of $2.95.
Separately, ValuEngine raised shares of Chiasma from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
TRADEMARK VIOLATION WARNING: This article was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.thelincolnianonline.com/2018/03/13/chiasma-chma-to-release-quarterly-earnings-on-wednesday.html.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.